BioSpace News Archive

Business

Allakos Axes Half of Its Workforce, Drops Lead Inflammatory Candidate

The biotech Tuesday announced a restructuring plan as its humanized IgG1 antibody lirentelimab failed two Phase II studies in atopic dermatitis and chronic spontaneous urticaria.

January 16, 2024
·
2 min read
·
Tristan Manalac
Business

Pan Orion Invests $415M in Korean Biotech LegoChem, Secures Majority Stake

The snacks and confectionery giant has been seeking to enter the biopharmaceuticals space in recent years.

January 16, 2024
·
2 min read
·
Tristan Manalac
FDA

FDA Approves Vertex, CRISPR’s Casgevy to Treat Beta Thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics have secured another FDA approval for their Casgevy Cas9 gene-edited cell therapy, this time in treating transfusion-dependent beta thalassemia.

January 16, 2024
·
2 min read
·
Tyler Patchen
Deals

Alto, Kyverna Join Growing Number of Biotech IPO Filings in 2024

Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.

January 16, 2024
·
2 min read
·
Tristan Manalac
Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates?

The Gates Foundation and some biotechs are betting that the technology could be deployed at scale.

January 16, 2024
·
5 min read
·
Shawna Williams
Business

AbbVie-Backed Disco Launches with $20M in Funding, Targets Oncology

Disco Pharmaceuticals is taking to the biotech dance floor with seed funding from major players and pipeline programs in small cell lung cancer and colorectal cancer.

January 16, 2024
·
2 min read
·
Tyler Patchen
Despite Tough Market, Some Life Science IPOs Find Success

The handful of biotechs that went public in 2023 fared well, providing hope to a cautiously optimistic sector.

January 16, 2024
·
4 min read
·
Mollie Barnes
Biotech Beach

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU’s First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

Halozyme Therapeutics, Inc. announced that Roche received European Commission marketing authorization of Tecentriq® SC co-formulated with ENHANZE®, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20.

January 16, 2024
·
6 min read
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements

Stalicla SA announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.

January 16, 2024
·
2 min read
Policy

ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

ANI Pharmaceuticals, Inc. announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Indomethacin Oral Suspension, USP.

January 16, 2024
·
3 min read